Is Lisraya, the First Pill for Dermatomyositis, Right for You?

The short version: Lisraya (brepocitinib) is a 30 mg pill taken once daily, and it fits adults whose disease keeps breaking through steroids plus at least one other immunosuppressant. It earned its label with a randomized phase 3 trial in exactly that group. It also carries the JAK-class boxed warning and a steep price tag, which is why the fit is narrower than the headline sounds.

The shelf before Lisraya

Adult dermatomyositis has been treated with a stack of drugs mostly borrowed from other diseases. Steroids do the initial heavy lifting, but about half of people on steroids alone relapse when the dose is tapered. That's why methotrexate, mycophenolate, or azathioprine get added early, though none of the three has ever been compared head-to-head in a controlled trial. A four-center retrospective study of 100 patients found no meaningful difference between them for muscle strength or cumulative steroid exposure.

The one prior therapy with a positive phase 3 trial was IVIG. In ProDERM, 79% of adults on IVIG reached at least minimal improvement at 16 weeks versus 44% on placebo, and skin activity fell substantially. Rituximab is used off-label for refractory disease, with case series reporting response in roughly two-thirds of people, though its one randomized trial missed its primary endpoint. Tofacitinib, ruxolitinib, and baricitinib have been tried off-label from case series and small open-label studies. Mostly uncontrolled evidence, one solid IVIG trial, a handful of promising JAK signals. That's the shelf.

What VALOR actually showed

VALOR randomized 241 adults with treatment-resistant dermatomyositis to brepocitinib 30 mg, 15 mg, or placebo on top of continued standard therapy, with steroids tapered per protocol. At 52 weeks, the 30 mg group scored about 47 on the Total Improvement Score against 31 on placebo. That's a 15-point gap on a 0-to-100 composite that captures physician and patient assessment, muscle strength, function, and lab markers.

The gap held on every one of the nine key secondary endpoints: skin activity, functional disability, and glucocorticoid tapering all favored brepocitinib, with benefits showing up by week 4. The 15 mg dose didn't separate from placebo, which is why the approved dose is 30 mg. It's the strongest evidence base dermatomyositis has ever had for a drug developed specifically for it.

Where the price and the warning bite

Serious infections landed on 10% of the 30 mg group versus 1% on placebo. No deaths in the trial, but that gap matters for anyone with a history of recurrent infection. The label carries the JAK-class boxed warning for serious infections, all-cause mortality, cancer, major cardiovascular events, and blood clots. That warning was derived from tofacitinib's ORAL Surveillance trial in rheumatoid arthritis patients over 50 with cardiovascular risk factors. The signal isn't uniform across every JAK inhibitor or every disease, and long-term data specific to brepocitinib in dermatomyositis don't yet exist. Herpes zoster is the most consistently elevated infection across the class. The label also flags hypersensitivity, gastrointestinal perforation, hypoglycemia in patients with diabetes, and lab changes including neutropenia, lymphopenia, anemia, and lipid elevations.

Then there's the price. Lisraya's list is roughly $35,000 for a 30-day supply. Distribution runs through a specialty pharmacy network, and the manufacturer offers a copay program (LISRAYA My Compass Support) for eligible commercially insured patients. For everyone else, insurance coverage will decide whether this drug is real or theoretical.

Who this actually fits

If your dermatomyositis is still active after steroids plus at least one immunosuppressant, Lisraya is worth pursuing. It cuts skin disease. It improves function. It lets you come off steroids faster. It's a pill, not an infusion. And for the first time, all of that rests on a randomized trial in this exact disease.

If you're newly diagnosed, mild, or already well controlled on standard therapy plus IVIG, it's a harder sell. VALOR only enrolled treatment-resistant adults, so the evidence doesn't yet cover first-line use. The boxed warning weighs heaviest if you're over 50 or carry cardiovascular, clotting, infection, or cancer risk, which is why a rheumatologist or dermatologist experienced in myositis is the right person to walk through the trade-off with you. The label is adult-only for now; children with juvenile dermatomyositis aren't covered.

What would change the answer

A head-to-head trial against IVIG or rituximab. Longer-term safety data on brepocitinib specific to dermatomyositis, showing whether the class signals for heart events, clots, and cancer actually materialize here. A trial in newly diagnosed rather than treatment-resistant patients. A pediatric label. Updated ACR or EULAR guidelines placing brepocitinib in the treatment algorithm. Until any of those land, the case for Lisraya is narrower than 'everyone with dermatomyositis' but real: for the patient whose disease has kept breaking through every drug they've tried, this is the first time the pharmacy shelf, not just the infusion suite, has something to offer.